PMID- 37686645
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230911
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 15
IP  - 17
DP  - 2023 Sep 1
TI  - Effectiveness and Safety of Palbociclib Plus Endocrine Therapy in Patients with 
      Advanced Breast Cancer: A Multi-Center Study in China.
LID - 10.3390/cancers15174360 [doi]
LID - 4360
AB  - BACKGROUND: Palbociclib has been approved for marketing in China. However, its 
      effectiveness, safety, and latent variables in the Chinese population require 
      further investigation. METHODS: Information was retrieved from 397 patients with 
      metastatic breast cancer (mBC) who received at least two cycles of palbociclib 
      plus endocrine therapy (PAL plus ET) at eight clinical sites in China. The 
      patients' demographic characteristics, treatment patterns, and adverse events 
      (AEs) were analyzed. RESULTS: The objective response rate (ORR) and clinical 
      benefit rate (CBR) for PAL plus ET were 28.97% and 66.25%, respectively. The 
      median PFS was 14.2 months in the whole population. In addition to protein Ki-67 
      status and sensitivity to ETs, no liver metastases, fewer metastatic sites, an 
      earlier line of therapy, and treatment combined with AI instead of FUL were also 
      considered as independent prognostic factors for PAL treatment. Administration of 
      PAL was generally well tolerated in patients with hormone-receptor-positive and 
      human-epidermal-growth-factor-receptor-2-negative (HR+/HER2-) advanced breast 
      cancer (ABC). The therapy was safe in the elderly population, which is consistent 
      with the outcomes of the whole population and previous reports. CONCLUSIONS: In 
      this most widely distributed study in China to date, palbociclib combined with ET 
      proved its effectiveness for HR+/HER2- ABC treatment, and adverse events were 
      manageable. Here, we identified some independent prognosis factors, but the 
      mechanism by which these factors influence effectiveness requires further 
      verification.
FAU - Wu, Xinyu
AU  - Wu X
AUID- ORCID: 0009-0006-5459-298X
AD  - Department of Medicine, Nanjing Medical University, Nanjing 210029, China.
AD  - Department of Oncology, The First Affiliated Hospital of Nanjing Medical 
      University, Nanjing 210029, China.
FAU - Jin, Nan
AU  - Jin N
AD  - Department of Medicine, Nanjing Medical University, Nanjing 210029, China.
AD  - Department of Oncology, The First Affiliated Hospital of Nanjing Medical 
      University, Nanjing 210029, China.
FAU - Gao, Hongfei
AU  - Gao H
AD  - Department of Breast Cancer, Cancer Center, Guangdong Provincial People's 
      Hospital, Southern Medical University, Guangzhou 510515, China.
FAU - Yan, Min
AU  - Yan M
AD  - Department of Breast Disease, Henan Breast Cancer Center, The Affiliated Cancer 
      Hospital of Zhengzhou University, Zhengzhou 450008, China.
FAU - Chen, Qianjun
AU  - Chen Q
AD  - Department of Breast Disease, Guangdong Provincial Hospital of Chinese Medicine, 
      Guangzhou 510120, China.
FAU - Sun, Tao
AU  - Sun T
AD  - Department of Medical Oncology, Liaoning Cancer Hospital & Institute, Shenyang 
      110042, China.
FAU - Hao, Chunfang
AU  - Hao C
AD  - Department of Breast Oncology, Tianjin Medical University Cancer Institute and 
      Hospital, Tianjin 300060, China.
FAU - Zhao, Yanxia
AU  - Zhao Y
AD  - Union Hospital, Tongji Medical College, Huazhong University of Science and 
      Technology, Wuhan 430074, China.
FAU - Han, Xinhua
AU  - Han X
AD  - Division of Life Science and Medicine, Department of Oncology, The First 
      Affiliated Hospital of University of Science and Technology of China (USTC), 
      University of Science and Technology of China, Hefei 230026, China.
FAU - Pan, Yueyin
AU  - Pan Y
AD  - Division of Life Science and Medicine, Department of Oncology, The First 
      Affiliated Hospital of University of Science and Technology of China (USTC), 
      University of Science and Technology of China, Hefei 230026, China.
FAU - Huang, Xiang
AU  - Huang X
AUID- ORCID: 0000-0002-7448-1711
AD  - Department of Medicine, Nanjing Medical University, Nanjing 210029, China.
AD  - Department of Oncology, The First Affiliated Hospital of Nanjing Medical 
      University, Nanjing 210029, China.
FAU - Li, Wei
AU  - Li W
AD  - Department of Medicine, Nanjing Medical University, Nanjing 210029, China.
AD  - Department of Oncology, The First Affiliated Hospital of Nanjing Medical 
      University, Nanjing 210029, China.
FAU - Wang, Kun
AU  - Wang K
AD  - Department of Breast Cancer, Cancer Center, Guangdong Provincial People's 
      Hospital, Southern Medical University, Guangzhou 510515, China.
FAU - Yin, Yongmei
AU  - Yin Y
AUID- ORCID: 0000-0003-3335-369X
AD  - Department of Medicine, Nanjing Medical University, Nanjing 210029, China.
AD  - Department of Oncology, The First Affiliated Hospital of Nanjing Medical 
      University, Nanjing 210029, China.
LA  - eng
GR  - YXJL-2020-0941-0761/Beijing Medical Award Foundation/
PT  - Journal Article
DEP - 20230901
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC10487219
OTO - NOTNLM
OT  - metastatic breast cancer
OT  - palbociclib
OT  - real-world study
COIS- The authors declare no conflict of interest.
EDAT- 2023/09/09 11:45
MHDA- 2023/09/09 11:46
PMCR- 2023/09/01
CRDT- 2023/09/09 01:15
PHST- 2023/07/15 00:00 [received]
PHST- 2023/08/23 00:00 [revised]
PHST- 2023/08/29 00:00 [accepted]
PHST- 2023/09/09 11:46 [medline]
PHST- 2023/09/09 11:45 [pubmed]
PHST- 2023/09/09 01:15 [entrez]
PHST- 2023/09/01 00:00 [pmc-release]
AID - cancers15174360 [pii]
AID - cancers-15-04360 [pii]
AID - 10.3390/cancers15174360 [doi]
PST - epublish
SO  - Cancers (Basel). 2023 Sep 1;15(17):4360. doi: 10.3390/cancers15174360.